NCT00219765TerminatedPhase 1
Phase I/II Trial to Study the Dose, Tolerability and the Effectiveness of Imatinib in Combination With Daunorubicine and Cytarabine for Patients With Chronic Myelogenous Leukemia in Myeloid Acute Phase
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Poitiers University Hospital
- Enrollment
- 30
- Locations
- 2
- Primary Endpoint
- To assess the tolerability and the effectiveness of imatinib in combination with daunorubicine and cytarabine and to determine the recommended dose of daunorubicine to be associated with cytarabine
Study Overview
Brief Summary
The aim of this phase I/II trial is to determine the dose of daunorubicine to be associated with cytarabine and Imatinib for induction therapy in patients with chronic myelogenous leukemia in myeloid acute phase.
Detailed Description
Study design Imatinib: starting at day -3: 600mg/day; continuous administration In combination with cytarabine: continuous iv/24h: 100mg/m² ; 7 days and daunorubicine: 4 levels
level 1: 0
level 2: 15mg/m² ; 3 days
level 3: 30mg/m² ; 3 days
level 4: 45mg/m² ; 3 days
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •CML Ph+ (assessed by cytogenetic or FISH)
- •Acute phase with ≥ 20% bone marrow blasts (M0 to M6 , excluding M3)
- •Age ≥ 18 year at inclusion
- •PS grade 0 to 2 (ECOG)
- •Adequate and organ function, defined as the following: total bilirubin <1.5x uln, sgpt <3x uln, creatinine <1.5x uln.
- •Informed consent signed up
Exclusion Criteria
- •active malignancy other than CML or non-melanoma cancer of the skin
- •current treatment with another investigational agent
- •patients with grade 3/4 cardiac disease or any other serious concurrent medical condition.
- •patients who are pregnant or nursing. All patients of childbearing potential must practice effective methods of contraception while on study.
- •patients with mental illness or other condition precluding their ability to give informed consent or to comply with study requirements patients with performans status 3-4
Outcomes
Primary Outcomes
To assess the tolerability and the effectiveness of imatinib in combination with daunorubicine and cytarabine and to determine the recommended dose of daunorubicine to be associated with cytarabine
Secondary Outcomes
- - To evaluate the survival without progression, the survival without event, the overall survival, the hematologic, cytogenetic and molecular responses at various check points.
- - To evaluate duration of responses and failure to respond
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Terminated
Phase 1
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I PortionMelanomaNCT00791271M.D. Anderson Cancer Center17
Completed
Phase 2
ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungNCT00071188Genzyme, a Sanofi Company
Completed
Phase 2
OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)Primary Mitochondrial DiseaseNCT05972954Omeicos Therapeutics GmbH28
Completed
Phase 1
Phase 1b Study of DCR-AUD in Healthy VolunteersAlcohol Use DisorderNCT05845398Dicerna Pharmaceuticals, Inc., a Novo Nordisk company16
Terminated
Phase 1
Phase l/II Study of Ruxolitinib for Acute LeukemiaLeukemiaNCT01251965M.D. Anderson Cancer Center27